Supplementary Table S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Danny Rischin; Aaron Richard Hansen; Ezra E.W. Cohen; Makoto Tahara; Kevin Joseph Harrington; Robert I. Haddad; Lisa Francesca Licitra; Hisham Mohamed Mehanna; Robert Louis Ferris; P. Koralewski; Konstantin Penkov; Michael Schenker; David Robert Spigel; Amaury Daste; Min Hee Hong; Ye Guo; Michael Jon Chisamore; Michael L. Washburn; Amy Phillips‐Jones; John Russell; Sumita Roy–Ghanta; Catherine E. Ellis; Marc S. Ballas; Christophe Le Tourneau

doi:10.1158/1078-0432.31744709

Supplementary Table S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2026 Open access

Read full text

Authors: Danny Rischin, Aaron Richard Hansen, Ezra E.W. Cohen, Makoto Tahara, Kevin Joseph Harrington, Robert I. Haddad, Lisa Francesca Licitra, Hisham Mohamed Mehanna, Robert Louis Ferris, P. Koralewski, Konstantin Penkov, Michael Schenker

+12 more

David Robert Spigel, Amaury Daste, Min Hee Hong, Ye Guo, Michael Jon Chisamore, Michael L. Washburn, Amy Phillips‐Jones, John Russell, Sumita Roy–Ghanta, Catherine E. Ellis, Marc S. Ballas, Christophe Le Tourneau

DOI: 10.1158/1078-0432.31744709

Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Head and Neck Cancer Studies Nonmelanoma Skin Cancer Studies

Publication details

Publication date: 16 March 2026
Language: EN